ERNA ERNA
Company Profile ↓Company Overview
ERNA (ERNA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +755.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -25.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -25.19% |
| 1 Year: | 755.88% |
Stock Price Performance
| 1 Year: | -89.49% |
| 6 Months: | -82.17% |
| 3 Months: | +2.76% |
| 1 Month: | -33.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -25.2% CAGR over 5 years.
- Trading 91.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.55M | 5.20M | 5.76M | 5.65M | 6.00M | 4.83M | 5.23M | 4.58M | 2.39M | 754.00K | 1.48M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | -50.00K | - | -69.00K | -14.00K | -48.00K | 547.00K | - | - | - | - |
| Operating Income | -366.00K | -115.00K | -236.00K | -654.00K | -1.30M | -1.27M | -2.21M | -2.47M | -1.31M | -868.00K | -696.00K | -414.00K | -834.00K | -26.00K | -53.00K | -313.00K | -27.00K | 370.00K | -217.00K | -2.00K | -316.00K | -1.01M | -2.02M | -2.01M | -8.92M | -10.01M | -86.28M | -6.30M | -13.88M | -8.30M | -5.32M | -4.55M | -5.50M | -5.79M | -4.93M | -2.26M | -2.73M | -2.50M | -1.99M | -5.59M |
| Net Income | -369.00K | -99.00K | -234.00K | -649.00K | -1.35M | -1.31M | -2.26M | -2.62M | -1.35M | -1.04M | -850.00K | -573.00K | -90.00K | -164.00K | -184.00K | -409.00K | -124.00K | 222.00K | -313.00K | -90.00K | -351.00K | -1.02M | -2.03M | -2.02M | -18.52M | -10.09M | -85.99M | -9.38M | -3.40M | -7.32M | -5.42M | -4.51M | -5.59M | -6.65M | -5.53M | -26.60M | -8.20M | -3.14M | -1.24M | -5.51M |
| Diluted EPS | - | - | 0.00 | - | - | - | - | - | - | - | - | - | - | - | -0.07 | - | - | 0.08 | - | - | - | -0.06 | -0.12 | -0.11 | -0.67 | -0.24 | -34.03 | -3.50 | -1.16 | -2.49 | -1.06 | -0.85 | -1.03 | -1.23 | -15.34 | -73.70 | -57.76 | -0.61 | -0.15 | -6.95 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.53M | 5.43M | - | 1.78M | 1.69M | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.31M | 23.87M | 24.06M | 23.75M | 26.05M | 24.52M | 22.31M | 21.27M | 23.34M | 19.81M | 5.80M | - | 0 | 68.00K | 582.00K | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 0 | -168.00K | 486.00K | - |
| Operating Income | -325.00K | -3.28M | -1.06M | -1.12M | -4.74M | -6.89M | -2.28M | -1.40M | 203.00K | -1.76M | -26.49M | -113.73M | -33.22M | -21.14M | -15.67M | -9.32M |
| Net Income | -400.00K | -3.42M | -995.00K | -1.05M | -5.03M | -7.23M | -2.92M | -1.08M | -259.00K | -2.05M | -26.53M | -122.55M | -24.58M | -21.67M | -44.54M | -14.08M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -1.51 | -56.61 | -8.06 | -4.08 | -48.96 | -2.24 |
| R&D Expense | - | - | - | - | - | - | - | 139.00K | 72.00K | 26.00K | 2.00K | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 13.12M | 11.65M | 12.66M | 15.46M | 22.27M | 16.41M | 16.70M | 16.57M | 14.86M | 14.12M | 13.78M | 31.52M | 22.28M | 49.13M | 5.27M | 5.83M |
| Total Equity | 9.42M | 9.46M | 6.35M | 7.89M | 9.20M | 10.92M | 3.85M | 4.07M | 5.54M | 6.92M | 9.74M | 7.66M | 25.50M | 12.11M | 2.23M | 1.70M | 2.40M |
| Cash & Equivalents | 3.64M | 3.91M | 1.37M | 2.72M | 5.46M | 7.18M | 3.22M | 5.69M | 3.38M | 2.54M | 3.21M | 777.00K | 16.98M | 11.45M | 7.58M | 1.73M | - |
| Long Term Debt | - | - | - | - | 1.59M | 5.32M | 7.44M | 8.11M | 5.12M | 3.75M | - | 532.00K | - | - | - | - | - |
| Total Liabilities | - | 3.66M | 5.30M | 4.76M | 6.25M | 11.34M | 12.56M | 12.63M | 11.03M | 7.95M | 9.03M | 25.36M | 6.02M | 10.17M | 46.90M | 3.57M | 3.43M |
| Current Liabilities | - | 3.34M | 3.87M | 3.39M | 3.61M | 7.09M | 5.12M | 6.64M | 10.75M | 4.02M | 6.09M | 3.12M | 3.68M | 7.65M | 6.57M | 2.94M | 3.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.83M | 574.00K | 2.16M | - | - | -4.18M | 23.00K | 549.00K | 1.36M | 2.74M | -8.10M | -23.49M | -20.98M | -20.41M | -15.84M | -7.02M |
| Investing Cash Flow | -2.20M | -2.79M | -2.78M | - | - | -1.62M | -840.00K | -1.45M | -1.58M | -1.06M | -39.00K | -22.74M | -47.00K | -19.00K | -365.00K | -37.00K |
| Financing Cash Flow | -364.00K | -300.00K | 1.95M | - | - | 1.98M | 3.26M | -1.47M | -303.00K | -1.10M | 4.67M | 61.59M | 19.58M | 16.56M | 6.26M | 7.21M |
| Capital Expenditure | -1.32M | -1.59M | -1.23M | -1.11M | -835.00K | -991.00K | -427.00K | -728.00K | -648.00K | -128.00K | -39.00K | -154.00K | -297.00K | -19.00K | -369.00K | -37.00K |
| Free Cash Flow | 1.51M | -1.02M | 930.00K | - | - | -5.17M | -404.00K | -179.00K | 717.00K | 2.62M | -8.14M | -23.64M | -21.27M | -20.43M | -16.20M | -7.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | -247.1% | 83.5% | - |
| Operating Margin % | -1.3% | -13.7% | -4.4% | -4.7% | -18.2% | -28.1% | -10.2% | -6.6% | 0.9% | -8.9% | -456.7% | - | - | -31,080.9% | -2,693.1% | - |
| Net Margin % | -1.6% | -14.3% | -4.1% | -4.4% | -19.3% | -29.5% | -13.1% | -5.1% | -1.1% | -10.3% | -457.4% | - | - | -31,864.7% | -7,652.7% | - |
| ROE % | -4.2% | -53.8% | -12.6% | -11.4% | -46.0% | -187.8% | -71.9% | -19.5% | -3.7% | -21.0% | -346.4% | -480.5% | -203.0% | -970.4% | -2,618.4% | -586.6% |
| ROCE % | -3.3% | -42.1% | -11.5% | -9.4% | -31.2% | -61.1% | -22.7% | -24.1% | 1.9% | -21.9% | -248.7% | -408.4% | -227.1% | -49.7% | -672.4% | -342.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ERNA
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System Video Showcases Differentiated Off-the-Shelf Cell T…
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
Ernexa Therapeutics (NASDAQ:ERNA) shares surged 30% on Wednesday after the company announced positive independent preclinical data supporting its lead cell therapy candidate, ERNA-101, for the treatment of ovarian cancer. Independent resear…
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND ERNA-101 Plus Anti-PD-1 Achieved Complete Tumor Clearance and Long-Term Sur…
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform and progress toward …
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
New platform provides additional perspective on Ernexa's mission to deliver hope for patients through innovative, scalable cell therapies while improving accessibility and affordability Inaugural video highlights Company's mission to provid…
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027CAMBRIDGE, Mass., June 17, 2026 (GLOBE …
ERNA — Frequently Asked Questions
What is the current share price of ERNA?
As of 2026-08-05 17:25 PDT, ERNA trades at $4.10 on NASDAQ/NYSE. Its 52-week range is $3.28 to $47.00.
What is the P/E ratio of ERNA?
ERNA trades at a trailing price-to-earnings (P/E) ratio of -1.83.
Is ERNA a good stock to buy?
This page provides a data-driven analysis of ERNA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.